カテゴリー： GlobalInfoResearch, 世界, 医療/バイオ

世界のインフルエンザNA阻害剤市場2022年：ザナミビル、オセルタミビル、ペラミビル

◆英語タイトル：Global Influenza NA Inhibitor Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

GlobalInfoResearchが発行した調査報告書（GIR22MY8855）◆商品コード：GIR22MY8855
◆発行会社（リサーチ会社）：GlobalInfoResearch
◆発行日：2022年5月（※2025年版があります。お問い合わせください。）
◆ページ数：91
◆レポート形式：英語 / PDF
◆納品方法：Eメール（注文後2-3日）
◆調査対象地域：グローバル
◆産業分野：医薬品
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

インフルエンザNA阻害剤市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界のインフルエンザNA阻害剤の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

インフルエンザNA阻害剤市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・ザナミビル、オセルタミビル、ペラミビル

用途別セグメントは次のように区分されます。
・インフルエンザA型治療、インフルエンザB型治療

世界のインフルエンザNA阻害剤市場の主要な市場プレーヤーは以下のとおりです。
・Green Cross、Roche、GlaxoSmithKline、Henan DaKen Chemical、ATK Chemical、Chemwill Asia Co.,Ltd.、Shionogi Co.、NeoPharm、Moksha8 Pharma

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、インフルエンザNA阻害剤製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要なインフルエンザNA阻害剤メーカーの企業概要、2019年～2022年までのインフルエンザNA阻害剤の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要なインフルエンザNA阻害剤メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別インフルエンザNA阻害剤の販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までのインフルエンザNA阻害剤の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域でのインフルエンザNA阻害剤市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、およびインフルエンザNA阻害剤の産業チェーンを掲載しています。
・第13、14、15章では、インフルエンザNA阻害剤の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
・メーカー情報（企業概要、製品概要、販売量、価格、売上）：Green Cross、Roche、GlaxoSmithKline、Henan DaKen Chemical、ATK Chemical、Chemwill Asia Co.,Ltd.、Shionogi Co.、NeoPharm、Moksha8 Pharma
・メーカー別市場シェア
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：ザナミビル、オセルタミビル、ペラミビル
・用途別分析2017年-2028年：インフルエンザA型治療、インフルエンザB型治療
・インフルエンザNA阻害剤の北米市場規模2017年-2028年：アメリカ、カナダ、メキシコ
・インフルエンザNA阻害剤のヨーロッパ市場規模2017年-2028年：ドイツ、イギリス、フランス、ロシア、イタリア
・インフルエンザNA阻害剤のアジア市場規模2017年-2028年：中国、日本、韓国、インド、東南アジア、オーストラリア
・インフルエンザNA阻害剤の南米市場規模2017年-2028年：ブラジル、アルゼンチン
・インフルエンザNA阻害剤の中東・アフリカ市場規模2017年-2028年：サウジアラビア、トルコ、エジプト、南アフリカ
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Influenza NA Inhibitor market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Influenza NA Inhibitor market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Influenza A Treatment accounting for % of the Influenza NA Inhibitor global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Zanamivir segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Influenza NA Inhibitor include Green Cross, Roche, GlaxoSmithKline, Henan DaKen Chemical, and ATK Chemical, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Influenza NA Inhibitor market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Zanamivir
Oseltamivir
Peramivir
Market segment by Application can be divided into
Influenza A Treatment
Influenza B Treatment
The key market players for global Influenza NA Inhibitor market are listed below:
Green Cross
Roche
GlaxoSmithKline
Henan DaKen Chemical
ATK Chemical
Chemwill Asia Co.,Ltd.
Shionogi Co.
NeoPharm
Moksha8 Pharma
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Influenza NA Inhibitor product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Influenza NA Inhibitor, with price, sales, revenue and global market share of Influenza NA Inhibitor from 2019 to 2022.
Chapter 3, the Influenza NA Inhibitor competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Influenza NA Inhibitor breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Influenza NA Inhibitor market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Influenza NA Inhibitor.
Chapter 13, 14, and 15, to describe Influenza NA Inhibitor sales channel, distributors, customers, research findings and conclusion, appendix and data source.

❖ レポートの目次 ❖

1 Market Overview
1.1 Influenza NA Inhibitor Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Influenza NA Inhibitor Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Zanamivir
1.2.3 Oseltamivir
1.2.4 Peramivir
1.3 Market Analysis by Application
1.3.1 Overview: Global Influenza NA Inhibitor Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Influenza A Treatment
1.3.3 Influenza B Treatment
1.4 Global Influenza NA Inhibitor Market Size & Forecast
1.4.1 Global Influenza NA Inhibitor Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Influenza NA Inhibitor Sales in Volume (2017-2028)
1.4.3 Global Influenza NA Inhibitor Price (2017-2028)
1.5 Global Influenza NA Inhibitor Production Capacity Analysis
1.5.1 Global Influenza NA Inhibitor Total Production Capacity (2017-2028)
1.5.2 Global Influenza NA Inhibitor Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Influenza NA Inhibitor Market Drivers
1.6.2 Influenza NA Inhibitor Market Restraints
1.6.3 Influenza NA Inhibitor Trends Analysis
2 Manufacturers Profiles
2.1 Green Cross
2.1.1 Green Cross Details
2.1.2 Green Cross Major Business
2.1.3 Green Cross Influenza NA Inhibitor Product and Services
2.1.4 Green Cross Influenza NA Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Roche
2.2.1 Roche Details
2.2.2 Roche Major Business
2.2.3 Roche Influenza NA Inhibitor Product and Services
2.2.4 Roche Influenza NA Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 GlaxoSmithKline
2.3.1 GlaxoSmithKline Details
2.3.2 GlaxoSmithKline Major Business
2.3.3 GlaxoSmithKline Influenza NA Inhibitor Product and Services
2.3.4 GlaxoSmithKline Influenza NA Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Henan DaKen Chemical
2.4.1 Henan DaKen Chemical Details
2.4.2 Henan DaKen Chemical Major Business
2.4.3 Henan DaKen Chemical Influenza NA Inhibitor Product and Services
2.4.4 Henan DaKen Chemical Influenza NA Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 ATK Chemical
2.5.1 ATK Chemical Details
2.5.2 ATK Chemical Major Business
2.5.3 ATK Chemical Influenza NA Inhibitor Product and Services
2.5.4 ATK Chemical Influenza NA Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Chemwill Asia Co.,Ltd.
2.6.1 Chemwill Asia Co.,Ltd. Details
2.6.2 Chemwill Asia Co.,Ltd. Major Business
2.6.3 Chemwill Asia Co.,Ltd. Influenza NA Inhibitor Product and Services
2.6.4 Chemwill Asia Co.,Ltd. Influenza NA Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Shionogi Co.
2.7.1 Shionogi Co. Details
2.7.2 Shionogi Co. Major Business
2.7.3 Shionogi Co. Influenza NA Inhibitor Product and Services
2.7.4 Shionogi Co. Influenza NA Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 NeoPharm
2.8.1 NeoPharm Details
2.8.2 NeoPharm Major Business
2.8.3 NeoPharm Influenza NA Inhibitor Product and Services
2.8.4 NeoPharm Influenza NA Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Moksha8 Pharma
2.9.1 Moksha8 Pharma Details
2.9.2 Moksha8 Pharma Major Business
2.9.3 Moksha8 Pharma Influenza NA Inhibitor Product and Services
2.9.4 Moksha8 Pharma Influenza NA Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Influenza NA Inhibitor Breakdown Data by Manufacturer
3.1 Global Influenza NA Inhibitor Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Influenza NA Inhibitor Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Influenza NA Inhibitor
3.4 Market Concentration Rate
3.4.1 Top 3 Influenza NA Inhibitor Manufacturer Market Share in 2021
3.4.2 Top 6 Influenza NA Inhibitor Manufacturer Market Share in 2021
3.5 Global Influenza NA Inhibitor Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Influenza NA Inhibitor Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Influenza NA Inhibitor Market Size by Region
4.1.1 Global Influenza NA Inhibitor Sales in Volume by Region (2017-2028)
4.1.2 Global Influenza NA Inhibitor Revenue by Region (2017-2028)
4.2 North America Influenza NA Inhibitor Revenue (2017-2028)
4.3 Europe Influenza NA Inhibitor Revenue (2017-2028)
4.4 Asia-Pacific Influenza NA Inhibitor Revenue (2017-2028)
4.5 South America Influenza NA Inhibitor Revenue (2017-2028)
4.6 Middle East and Africa Influenza NA Inhibitor Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Influenza NA Inhibitor Sales in Volume by Type (2017-2028)
5.2 Global Influenza NA Inhibitor Revenue by Type (2017-2028)
5.3 Global Influenza NA Inhibitor Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Influenza NA Inhibitor Sales in Volume by Application (2017-2028)
6.2 Global Influenza NA Inhibitor Revenue by Application (2017-2028)
6.3 Global Influenza NA Inhibitor Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Influenza NA Inhibitor Sales by Type (2017-2028)
7.2 North America Influenza NA Inhibitor Sales by Application (2017-2028)
7.3 North America Influenza NA Inhibitor Market Size by Country
7.3.1 North America Influenza NA Inhibitor Sales in Volume by Country (2017-2028)
7.3.2 North America Influenza NA Inhibitor Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Influenza NA Inhibitor Sales by Type (2017-2028)
8.2 Europe Influenza NA Inhibitor Sales by Application (2017-2028)
8.3 Europe Influenza NA Inhibitor Market Size by Country
8.3.1 Europe Influenza NA Inhibitor Sales in Volume by Country (2017-2028)
8.3.2 Europe Influenza NA Inhibitor Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Influenza NA Inhibitor Sales by Type (2017-2028)
9.2 Asia-Pacific Influenza NA Inhibitor Sales by Application (2017-2028)
9.3 Asia-Pacific Influenza NA Inhibitor Market Size by Region
9.3.1 Asia-Pacific Influenza NA Inhibitor Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Influenza NA Inhibitor Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Influenza NA Inhibitor Sales by Type (2017-2028)
10.2 South America Influenza NA Inhibitor Sales by Application (2017-2028)
10.3 South America Influenza NA Inhibitor Market Size by Country
10.3.1 South America Influenza NA Inhibitor Sales in Volume by Country (2017-2028)
10.3.2 South America Influenza NA Inhibitor Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Influenza NA Inhibitor Sales by Type (2017-2028)
11.2 Middle East & Africa Influenza NA Inhibitor Sales by Application (2017-2028)
11.3 Middle East & Africa Influenza NA Inhibitor Market Size by Country
11.3.1 Middle East & Africa Influenza NA Inhibitor Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Influenza NA Inhibitor Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Influenza NA Inhibitor and Key Manufacturers
12.2 Manufacturing Costs Percentage of Influenza NA Inhibitor
12.3 Influenza NA Inhibitor Production Process
12.4 Influenza NA Inhibitor Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Influenza NA Inhibitor Typical Distributors
13.3 Influenza NA Inhibitor Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global Influenza NA Inhibitor Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Influenza NA Inhibitor Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Green Cross Basic Information, Manufacturing Base and Competitors
Table 4. Green Cross Major Business
Table 5. Green Cross Influenza NA Inhibitor Product and Services
Table 6. Green Cross Influenza NA Inhibitor Sales (Kilotons), Price (US$/Kg), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Roche Basic Information, Manufacturing Base and Competitors
Table 8. Roche Major Business
Table 9. Roche Influenza NA Inhibitor Product and Services
Table 10. Roche Influenza NA Inhibitor Sales (Kilotons), Price (US$/Kg), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 12. GlaxoSmithKline Major Business
Table 13. GlaxoSmithKline Influenza NA Inhibitor Product and Services
Table 14. GlaxoSmithKline Influenza NA Inhibitor Sales (Kilotons), Price (US$/Kg), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Henan DaKen Chemical Basic Information, Manufacturing Base and Competitors
Table 16. Henan DaKen Chemical Major Business
Table 17. Henan DaKen Chemical Influenza NA Inhibitor Product and Services
Table 18. Henan DaKen Chemical Influenza NA Inhibitor Sales (Kilotons), Price (US$/Kg), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. ATK Chemical Basic Information, Manufacturing Base and Competitors
Table 20. ATK Chemical Major Business
Table 21. ATK Chemical Influenza NA Inhibitor Product and Services
Table 22. ATK Chemical Influenza NA Inhibitor Sales (Kilotons), Price (US$/Kg), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Chemwill Asia Co.,Ltd. Basic Information, Manufacturing Base and Competitors
Table 24. Chemwill Asia Co.,Ltd. Major Business
Table 25. Chemwill Asia Co.,Ltd. Influenza NA Inhibitor Product and Services
Table 26. Chemwill Asia Co.,Ltd. Influenza NA Inhibitor Sales (Kilotons), Price (US$/Kg), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Shionogi Co. Basic Information, Manufacturing Base and Competitors
Table 28. Shionogi Co. Major Business
Table 29. Shionogi Co. Influenza NA Inhibitor Product and Services
Table 30. Shionogi Co. Influenza NA Inhibitor Sales (Kilotons), Price (US$/Kg), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. NeoPharm Basic Information, Manufacturing Base and Competitors
Table 32. NeoPharm Major Business
Table 33. NeoPharm Influenza NA Inhibitor Product and Services
Table 34. NeoPharm Influenza NA Inhibitor Sales (Kilotons), Price (US$/Kg), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. Moksha8 Pharma Basic Information, Manufacturing Base and Competitors
Table 36. Moksha8 Pharma Major Business
Table 37. Moksha8 Pharma Influenza NA Inhibitor Product and Services
Table 38. Moksha8 Pharma Influenza NA Inhibitor Sales (Kilotons), Price (US$/Kg), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. Global Influenza NA Inhibitor Sales by Manufacturer (2019, 2020, 2021, and 2022) & (Kilotons)
Table 40. Global Influenza NA Inhibitor Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 41. Market Position of Manufacturers in Influenza NA Inhibitor, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 42. Global Influenza NA Inhibitor Production Capacity by Company, (Kilotons): 2020 VS 2021
Table 43. Head Office and Influenza NA Inhibitor Production Site of Key Manufacturer
Table 44. Influenza NA Inhibitor New Entrant and Capacity Expansion Plans
Table 45. Influenza NA Inhibitor Mergers & Acquisitions in the Past Five Years
Table 46. Global Influenza NA Inhibitor Sales by Region (2017-2022) & (Kilotons)
Table 47. Global Influenza NA Inhibitor Sales by Region (2023-2028) & (Kilotons)
Table 48. Global Influenza NA Inhibitor Revenue by Region (2017-2022) & (USD Million)
Table 49. Global Influenza NA Inhibitor Revenue by Region (2023-2028) & (USD Million)
Table 50. Global Influenza NA Inhibitor Sales by Type (2017-2022) & (Kilotons)
Table 51. Global Influenza NA Inhibitor Sales by Type (2023-2028) & (Kilotons)
Table 52. Global Influenza NA Inhibitor Revenue by Type (2017-2022) & (USD Million)
Table 53. Global Influenza NA Inhibitor Revenue by Type (2023-2028) & (USD Million)
Table 54. Global Influenza NA Inhibitor Price by Type (2017-2022) & (US$/Kg)
Table 55. Global Influenza NA Inhibitor Price by Type (2023-2028) & (US$/Kg)
Table 56. Global Influenza NA Inhibitor Sales by Application (2017-2022) & (Kilotons)
Table 57. Global Influenza NA Inhibitor Sales by Application (2023-2028) & (Kilotons)
Table 58. Global Influenza NA Inhibitor Revenue by Application (2017-2022) & (USD Million)
Table 59. Global Influenza NA Inhibitor Revenue by Application (2023-2028) & (USD Million)
Table 60. Global Influenza NA Inhibitor Price by Application (2017-2022) & (US$/Kg)
Table 61. Global Influenza NA Inhibitor Price by Application (2023-2028) & (US$/Kg)
Table 62. North America Influenza NA Inhibitor Sales by Country (2017-2022) & (Kilotons)
Table 63. North America Influenza NA Inhibitor Sales by Country (2023-2028) & (Kilotons)
Table 64. North America Influenza NA Inhibitor Revenue by Country (2017-2022) & (USD Million)
Table 65. North America Influenza NA Inhibitor Revenue by Country (2023-2028) & (USD Million)
Table 66. North America Influenza NA Inhibitor Sales by Type (2017-2022) & (Kilotons)
Table 67. North America Influenza NA Inhibitor Sales by Type (2023-2028) & (Kilotons)
Table 68. North America Influenza NA Inhibitor Sales by Application (2017-2022) & (Kilotons)
Table 69. North America Influenza NA Inhibitor Sales by Application (2023-2028) & (Kilotons)
Table 70. Europe Influenza NA Inhibitor Sales by Country (2017-2022) & (Kilotons)
Table 71. Europe Influenza NA Inhibitor Sales by Country (2023-2028) & (Kilotons)
Table 72. Europe Influenza NA Inhibitor Revenue by Country (2017-2022) & (USD Million)
Table 73. Europe Influenza NA Inhibitor Revenue by Country (2023-2028) & (USD Million)
Table 74. Europe Influenza NA Inhibitor Sales by Type (2017-2022) & (Kilotons)
Table 75. Europe Influenza NA Inhibitor Sales by Type (2023-2028) & (Kilotons)
Table 76. Europe Influenza NA Inhibitor Sales by Application (2017-2022) & (Kilotons)
Table 77. Europe Influenza NA Inhibitor Sales by Application (2023-2028) & (Kilotons)
Table 78. Asia-Pacific Influenza NA Inhibitor Sales by Region (2017-2022) & (Kilotons)
Table 79. Asia-Pacific Influenza NA Inhibitor Sales by Region (2023-2028) & (Kilotons)
Table 80. Asia-Pacific Influenza NA Inhibitor Revenue by Region (2017-2022) & (USD Million)
Table 81. Asia-Pacific Influenza NA Inhibitor Revenue by Region (2023-2028) & (USD Million)
Table 82. Asia-Pacific Influenza NA Inhibitor Sales by Type (2017-2022) & (Kilotons)
Table 83. Asia-Pacific Influenza NA Inhibitor Sales by Type (2023-2028) & (Kilotons)
Table 84. Asia-Pacific Influenza NA Inhibitor Sales by Application (2017-2022) & (Kilotons)
Table 85. Asia-Pacific Influenza NA Inhibitor Sales by Application (2023-2028) & (Kilotons)
Table 86. South America Influenza NA Inhibitor Sales by Country (2017-2022) & (Kilotons)
Table 87. South America Influenza NA Inhibitor Sales by Country (2023-2028) & (Kilotons)
Table 88. South America Influenza NA Inhibitor Revenue by Country (2017-2022) & (USD Million)
Table 89. South America Influenza NA Inhibitor Revenue by Country (2023-2028) & (USD Million)
Table 90. South America Influenza NA Inhibitor Sales by Type (2017-2022) & (Kilotons)
Table 91. South America Influenza NA Inhibitor Sales by Type (2023-2028) & (Kilotons)
Table 92. South America Influenza NA Inhibitor Sales by Application (2017-2022) & (Kilotons)
Table 93. South America Influenza NA Inhibitor Sales by Application (2023-2028) & (Kilotons)
Table 94. Middle East & Africa Influenza NA Inhibitor Sales by Region (2017-2022) & (Kilotons)
Table 95. Middle East & Africa Influenza NA Inhibitor Sales by Region (2023-2028) & (Kilotons)
Table 96. Middle East & Africa Influenza NA Inhibitor Revenue by Region (2017-2022) & (USD Million)
Table 97. Middle East & Africa Influenza NA Inhibitor Revenue by Region (2023-2028) & (USD Million)
Table 98. Middle East & Africa Influenza NA Inhibitor Sales by Type (2017-2022) & (Kilotons)
Table 99. Middle East & Africa Influenza NA Inhibitor Sales by Type (2023-2028) & (Kilotons)
Table 100. Middle East & Africa Influenza NA Inhibitor Sales by Application (2017-2022) & (Kilotons)
Table 101. Middle East & Africa Influenza NA Inhibitor Sales by Application (2023-2028) & (Kilotons)
Table 102. Influenza NA Inhibitor Raw Material
Table 103. Key Manufacturers of Influenza NA Inhibitor Raw Materials
Table 104. Direct Channel Pros & Cons
Table 105. Indirect Channel Pros & Cons
Table 106. Influenza NA Inhibitor Typical Distributors
Table 107. Influenza NA Inhibitor Typical Customers
List of Figures
Figure 1. Influenza NA Inhibitor Picture
Figure 2. Global Influenza NA Inhibitor Revenue Market Share by Type in 2021
Figure 3. Zanamivir
Figure 4. Oseltamivir
Figure 5. Peramivir
Figure 6. Global Influenza NA Inhibitor Revenue Market Share by Application in 2021
Figure 7. Influenza A Treatment
Figure 8. Influenza B Treatment
Figure 9. Global Influenza NA Inhibitor Revenue, (USD Million) & (Kilotons): 2017 & 2021 & 2028
Figure 10. Global Influenza NA Inhibitor Revenue and Forecast (2017-2028) & (USD Million)
Figure 11. Global Influenza NA Inhibitor Sales (2017-2028) & (Kilotons)
Figure 12. Global Influenza NA Inhibitor Price (2017-2028) & (US$/Kg)
Figure 13. Global Influenza NA Inhibitor Production Capacity (2017-2028) & (Kilotons)
Figure 14. Global Influenza NA Inhibitor Production Capacity by Geographic Region: 2022 VS 2028
Figure 15. Influenza NA Inhibitor Market Drivers
Figure 16. Influenza NA Inhibitor Market Restraints
Figure 17. Influenza NA Inhibitor Market Trends
Figure 18. Global Influenza NA Inhibitor Sales Market Share by Manufacturer in 2021
Figure 19. Global Influenza NA Inhibitor Revenue Market Share by Manufacturer in 2021
Figure 20. Influenza NA Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 21. Top 3 Influenza NA Inhibitor Manufacturer (Revenue) Market Share in 2021
Figure 22. Top 6 Influenza NA Inhibitor Manufacturer (Revenue) Market Share in 2021
Figure 23. Global Influenza NA Inhibitor Sales Market Share by Region (2017-2028)
Figure 24. Global Influenza NA Inhibitor Revenue Market Share by Region (2017-2028)
Figure 25. North America Influenza NA Inhibitor Revenue (2017-2028) & (USD Million)
Figure 26. Europe Influenza NA Inhibitor Revenue (2017-2028) & (USD Million)
Figure 27. Asia-Pacific Influenza NA Inhibitor Revenue (2017-2028) & (USD Million)
Figure 28. South America Influenza NA Inhibitor Revenue (2017-2028) & (USD Million)
Figure 29. Middle East & Africa Influenza NA Inhibitor Revenue (2017-2028) & (USD Million)
Figure 30. Global Influenza NA Inhibitor Sales Market Share by Type (2017-2028)
Figure 31. Global Influenza NA Inhibitor Revenue Market Share by Type (2017-2028)
Figure 32. Global Influenza NA Inhibitor Price by Type (2017-2028) & (US$/Kg)
Figure 33. Global Influenza NA Inhibitor Sales Market Share by Application (2017-2028)
Figure 34. Global Influenza NA Inhibitor Revenue Market Share by Application (2017-2028)
Figure 35. Global Influenza NA Inhibitor Price by Application (2017-2028) & (US$/Kg)
Figure 36. North America Influenza NA Inhibitor Sales Market Share by Type (2017-2028)
Figure 37. North America Influenza NA Inhibitor Sales Market Share by Application (2017-2028)
Figure 38. North America Influenza NA Inhibitor Sales Market Share by Country (2017-2028)
Figure 39. North America Influenza NA Inhibitor Revenue Market Share by Country (2017-2028)
Figure 40. United States Influenza NA Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 41. Canada Influenza NA Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Mexico Influenza NA Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 43. Europe Influenza NA Inhibitor Sales Market Share by Type (2017-2028)
Figure 44. Europe Influenza NA Inhibitor Sales Market Share by Application (2017-2028)
Figure 45. Europe Influenza NA Inhibitor Sales Market Share by Country (2017-2028)
Figure 46. Europe Influenza NA Inhibitor Revenue Market Share by Country (2017-2028)
Figure 47. Germany Influenza NA Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. France Influenza NA Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. United Kingdom Influenza NA Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Russia Influenza NA Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Italy Influenza NA Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Asia-Pacific Influenza NA Inhibitor Sales Market Share by Region (2017-2028)
Figure 53. Asia-Pacific Influenza NA Inhibitor Sales Market Share by Application (2017-2028)
Figure 54. Asia-Pacific Influenza NA Inhibitor Sales Market Share by Region (2017-2028)
Figure 55. Asia-Pacific Influenza NA Inhibitor Revenue Market Share by Region (2017-2028)
Figure 56. China Influenza NA Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Japan Influenza NA Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Korea Influenza NA Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. India Influenza NA Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Southeast Asia Influenza NA Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Australia Influenza NA Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. South America Influenza NA Inhibitor Sales Market Share by Type (2017-2028)
Figure 63. South America Influenza NA Inhibitor Sales Market Share by Application (2017-2028)
Figure 64. South America Influenza NA Inhibitor Sales Market Share by Country (2017-2028)
Figure 65. South America Influenza NA Inhibitor Revenue Market Share by Country (2017-2028)
Figure 66. Brazil Influenza NA Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Argentina Influenza NA Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. Middle East & Africa Influenza NA Inhibitor Sales Market Share by Type (2017-2028)
Figure 69. Middle East & Africa Influenza NA Inhibitor Sales Market Share by Application (2017-2028)
Figure 70. Middle East & Africa Influenza NA Inhibitor Sales Market Share by Region (2017-2028)
Figure 71. Middle East & Africa Influenza NA Inhibitor Revenue Market Share by Region (2017-2028)
Figure 72. Turkey Influenza NA Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Egypt Influenza NA Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Saudi Arabia Influenza NA Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. South Africa Influenza NA Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Manufacturing Cost Structure Analysis of Influenza NA Inhibitor in 2021
Figure 77. Manufacturing Process Analysis of Influenza NA Inhibitor
Figure 78. Influenza NA Inhibitor Industrial Chain
Figure 79. Sales Channel: Direct Channel vs Indirect Channel
Figure 80. Methodology
Figure 81. Research Process and Data Source


❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 世界のインフルエンザNA阻害剤市場2022年：ザナミビル、オセルタミビル、ペラミビル(Global Influenza NA Inhibitor Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 世界のノイラミニダーゼ阻害剤市場2022年：ザナミビル、オセルタミビル、ペラミビル、ラニナミビル
  • 世界のインフルエンザ用ワクチン市場2022年：三価インフルエンザ用ワクチン、四価インフルエンザ用ワクチン
  • 世界の犬用インフルエンザワクチン市場2022年：液体、粉体
  • 世界のインフルエンザ薬市場2022年：ザナミビル、オセルタミビル、ペラミビル、アマンタジン、リマンタジン、イノシン、その他
  • 世界の馬インフルエンザワクチン市場2022年：液体、粉末